The invention relates to 4-(substituent phenylamino group) quinazoline derivatives used as a tyrosine kinase inhibitor. Particularly, the invention relates to a compound shown in formula I, or pharmaceutically acceptable salt and solvate of the compound, wherein R is selected from a C1-6 alkyl sulfoxide group, one or more halogen-substituted C1-6 alkyl sulfoxide groups, a C1-6 alkyl sulfhydryl group, one or more halogen-substituted C1-6 alkyl sulfhydryl groups, a C1-6 alkyl amide group, a C1-6 alkyl sulfamide group, one or more halogen-substituted C1-6 alkyl sulfamide groups, one or more halogen-substituted C1-6 alkyl sulfonyl groups, or (R1R2)NS(O2)-; and R1 and R2 are respectively and independently selected from hydrogen, C1-6 alkyl groups and one or more halogen-substituted C1-6 alkyl groups. The invention also relates to a preparation method of the compound shown in the formula I, medicine composition containing the compound and pharmaceutical purposes of the compound and the medicine medicine. The compound shown in the formula I is an effective tyrosine kinase inhibitor.